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Abstract
AMIXICILE AS A NOVEL ANTIMICROBIAL TREATMENT FOR PERIODONTITIS: A
PILOT STUDY IN THE NON-HUMAN PRIMATE, MACACA MULATTA
By: Denver James Lyons, DDS
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science in Dentistry at Virginia Commonwealth University.
Virginia Commonwealth University, May 2020
Thesis Advisor: Dr. Janina Lewis, PhD
Professor and Director of Faculty Advancement
Department of Oral and Craniofacial Molecular Biology
Abstract: Periodontitis is an inflammatory disease with a bacterial etiology in a
susceptible host. Given the bacterial etiology, a selective antimicrobial agent with
minimal side effects could be a useful adjunct to traditional therapy. Amixicile is a novel
antimicrobial that targets the pyruvate: ferredoxin oxidoreductase (PFOR) which is an
enzyme that is critical for anaerobic bacterial metabolism. It has been found to have no
effect on commensal, aerobic microbes and has little to no side-effects thus far in
animal models. In this study, two nonhuman primates of the Macaca mulatta species
with naturally occurring mild chronic periodontitis were studied before and after a twoweek course of systemic administration of amixicile and at 3- and 6-months posttreatment. Periodontal charting including probing depths, clinical attachment levels,
presence of bleeding on probing, and presence of plaque was recorded at each visit in
addition to collecting saliva and subgingival plaque samples. The microbial composition
of the plaque and saliva was evaluated based on 16s rDNA analysis. Both animals’
clinical conditions saw a reduction in probing depths and clinical inflammation. In the
saliva samples a reduction in Porphyromonas, Fusobacterium, and Alloprevotella, all
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anaerobes, was seen with a concomitant increase in Streptococcus, Haemophilus,
Gemella, and Escherichia, all aerobes, was observed. Subgingival plaque samples
showed similar alterations in microbial composition. Reduction of Porphyromonas,
Fusobacterium, Prevotella, Veillonella, and Alloprevotella, all anaerobes, was observed
with concomitant increase of known aerobes. These changes generally take place
immediately post-treatment but return to baseline levels by 6-months. Thus, it was
concluded that due to its selectivity for anaerobic periodontal pathogens and lack of side
effects, amixicile is a strong candidate as a viable antimicrobial option for the treatment
of periodontal disease.

Key words: amixicile, antimicrobial, periodontal therapy, periodontitis, PFOR

Introduction
Periodontitis is an inflammatory disease with a bacterial etiology in a susceptible
host1. Given the bacterial etiology, antibiotics have been used regularly but judiciously
in the treatment of aggressive and severe chronic periodontitis cases. Antibiotics such
as amoxicillin, metronidazole, tetracycline, azithromycin, and clindamycin have been
studied and found to be effective2. These antibiotics, however, are broad-spectrum,
exerting their effects on both aerobic and anaerobic bacteria i.e. both commensal and
pathogenic flora, and, if used, serve as an adjunctive therapy3. It has been well
established that in health the microflora is dominated by aerobic species, especially
Streptococcus sp., while periodontitis is characterized by a shift to pathogenic,
anaerobic microorganisms4,5 (Figure 1). Thus, when a broad-spectrum antibiotic is
used, it will eliminate the aerobic bacteria allowing for reinfection by the pathogenic
anaerobic species, which enjoy the protection of biofilms in the forms of dental plaque
and calculus. Without the competition of the commensal aerobic species the anaerobes
can multiply in periodontal pockets which favor their proliferation. It is well established
that these pathogenic, anaerobic bacteria are found in periodontal pockets and include
such species as Porphyromonas gingivalis (P. gingivalis), Tannerella forsythia (T.
forsythia), and Treponema denticola (T. denticola) which make up the so-called "red
complex" while Campylobacter rectus (C. rectus), Fusobacterium nucleatum (F.
nucleatum), Parvimonas micra (P. micra), and Prevotella intermedia (P. intermedia)
comprise the “orange complex”6. In periodontally healthy sulci species such as
Actinomyces naeslundii (A. naeslundii), Streptococcus oralis (S. oralis), Streptococcus
gordonii (S. gordonii), Streptococcus cristatus (S. cristatus), Gemella haemolysans (G.
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Haemolysans), and Neisseria spp. are more abundant4. Finally, currently used
antibiotics do not eradicate bacteria that are internalized by host cells and serve as a
reservoir for re-infection.

Figure 1. This figure is adapted from the findings of Löe, 1965 showing the shift in the oral microflora from health
through gingivitis with the cessation of oral hygiene5.

Metronidazole is a semi-selective antibiotic that targets anaerobic species and
has been used as an adjunct to mechanical therapy in the treatment of aggressive and
refractory periodontitis7. It acts as a prodrug that is partially reduced inside of anaerobic
bacteria and some protozoans, which makes it selective for these populations. Once it
has been reduced into its active form, it disrupts bacterial nucleic acid synthesis8.
Metronidazole is generally used in combination with Amoxicillin as a very broadspectrum approach based on reducing the overall bacterial load. When used in
combination with Amoxicillin, significantly greater probing depth reduction and clinical
attachment gain was found compared to mechanical therapy alone9. When used alone
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Metronidazole was found to be effective in reducing the need for surgical therapy when
given in conjunction with traditional mechanical therapy7. Its use has been limited,
however, due to side effects including yeast infection, neuropathy, neurotoxicity,
pancreatitis, encephalopathy, and sometimes-severe gastrointestinal effects which can
lead to colitis if used repeatedly10. Thus, the need for a new antimicrobial agent that will
specifically target periodontal anaerobes with minimal to no side effects is apparent.
Criticism of the use of antibiotics in addition to mechanical therapy for the
treatment of periodontitis comes primarily due to unwanted side effects and contribution
to bacterial resistance11. Metronidazole has a very low occurrence of acquired
resistance due to its requirement to be taken into the cell and degraded into its active
form inside of anaerobic cells7. Similar selectivity in a substitute drug would be an
optimal characteristic.
Recently, the Hoffman laboratory at the University of Virginia, Department of
Medicine, has developed amixicile as an anaerobe-specific antimicrobial with a novel
mechanism to be used for the treatment of Clostridium difficile infections11. Amixicile is a
derivative of nitazoxanide in which a 2-acetoxy group has been replaced with an
aliphatic amine making the drug much more soluble as well as avoiding glucuronidation
in the liver. Using a murine model, the Hoffman lab was able to show a high degree of
specificity toward anaerobic gastrointestinal pathogens leaving commensal flora intact
with no notable side effects. This drug’s novel mechanism targets a vitamin B1
(thiamine pyrophosphate) cofactor involved in the pyruvate: ferredoxin oxidoreductase
(PFOR) metabolism essential to anaerobic bacteria. This highly specific target allows
both a high degree of anaerobe specificity as well as eliminating the risk of mutagenic
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bacterial resistance. Aerobic bacteria rely on pyruvate dehydrogenase (PDH) for
metabolism and thus are unaffected by treatment with amixicile. Even when given at
very high dosages that were well beyond the minimum inhibitory concentration (MIC) no
adverse effects were observed in the mice11.

Figure 2. Chemical structures of amixicile and its precursor nitazoxanide.

In addition to its effect on anaerobic bacteria, amixicile would seem to be a
candidate for treating periodontal infection due to its ability to localize at sites of
inflammation. This property was identified during studies on amixicile’s effect on C.
difficile infections and the mechanism has to do with mucosal inflammation which
causes local tissue destruction and serum leakage12. It is known that periodontal
disease causes localized tissue breakdown as evidenced by pocket formation which is
accompanied by an increase in gingival crevicular fluid which is an inflammatory
exudate derived from serum13. It was shown that amixicile is highly soluble reaching
high levels in serum thus it would be plausible that amixicile may localize to sites of
periodontal inflammation and be delivered to the sulcus via gingival crevicular fluid 11.
The next step in evaluating amixicile for potential periodontal therapy was to
verify that it would be effective on oral pathogens and in the oral environment. As stated
previously, certain periodontal pathogens are more virulent and contribute to greater
4

inflammation and dysbiosis than others. Given this fact, P. gingivalis, P. intermedia, F.
nucleatum, and T. forsythia were evaluated via the Kyoto Encyclopedia of Genes and
Genomes (KEGG) and all were found to have genes encoding for the PFOR enzyme
that has shown to be the target of amixicile. Known anaerobes, S. gordonii, and A.
actinomycetemcomitans, were found only to have genes encoding for PDH and thus
should be unaffected by amixicile. This was tested and confirmed using an in vitro
model in which it was found that amixicile inhibited the growth of P. gingivalis, P.
intermedia, F. nucleatum, and T. forsythia while it did not affect the growth of S. gordonii
nor A. actinomycetemcomitans in a monoculture environment. These microbes were
then combined into a multispecies culture that would represent the way they may live
and interact within a biofilm and again it was found that amixicile inhibited the growth of
P. gingivalis, P. intermedia, F. nucleatum, and T. forsythia, while it did not affect the
growth of S. gordonii nor A. actinomycetemcomitans in a multi-species environment.
The experiment was carried one step further with the addition of 10% saliva and 10%
serum to the multi-species culture to continue to simulate an oral environment and the
results continued to show that amixicile successfully and selectively targeted anaerobes
in a simulated oral environment14.
Continuing in the pre-clinical investigation of amixicile’s potential application in
treating periodontal disease, its efficacy in inhibiting Treponema denticola (T. denticola)
was evaluated. It has been found that in a healthy periodontium oral treponemes only
comprise about 1% of the sulcular microflora but in disease this proportion can reach
40-50%15. Again, it was shown in vitro that amixicile was a potent inhibitor of T.
denticola and its effect on some known virulence factors was elucidated. Amixicile was
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shown to inhibit both bacterial motility as well as reducing the production of hydrogen
sulfides which have been shown to induce apoptosis of cells of the human
periodontium16. Progressing to an ex vivo model using a well-developed oral salivary
microbiome derived from human subjects it was again shown that amixicile selectively
inhibited anaerobic bacteria containing the PFOR enzyme and that aerobic bacteria
were unaffected in a simulated oral environment representing a plaque biofilm17.
Finally, an ex vivo periodontal microbiome derived from gingival pockets of
patients with periodontal disease was used to determine amixicile’s efficacy in a
naturally derived biofilm. The importance of this is underscored by the fact that there is
a large diversity of bacterial strains in the periodontal microbiome, so it is essential to
test strains derived from clinical samples from diseased sites. Again, it was found that
amixicile was able to selectively inhibit anaerobes while sparing commensal aerobic
flora which can help prevent reinfection18.
Table 1. Genus and species of oral bacteria that rely on PFOR versus PDH for their metabolism of glucose. All
microbes relying on PFOR should be susceptible to amixicile, while those utilizing PDH should not.

PFOR Metabolism (Sensitive to
Amixicile)

PDH Metabolism

P. gingivalis, P. intermedia, F.
nucleatum, T. denticola, P. micra, and
T. forsythia. Porphyromonas spp.,
Veillonella spp., Prevotella spp.,
Alloprevotella spp., and Fusobacterium
spp.

S. gordonii, S. oralis, C. rectus, and A.
actinomycetemcomitans. Actinomyces spp.
Streptococcus spp., Klebsiella spp.,
Neisseria spp., Lactobacillus spp.,
Haemophilus spp., Gemella spp.,
Escherichia spp., and Leptotrichia spp.
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Figure 3. Representation of plaque biofilm showing early, middle, and late colonizers. Microbes are color-coded
according to either PDH or PFOR metabolism.

The present study will move the examination of amixicile into an in vivo,
preclinical animal model using the nonhuman primate (NHP), Macaca mulatta (M.
mulatta). In choosing an appropriate model for the study the anatomical, clinical, and
microbiological features of the animal should resemble the same features of a human
subject as closely as possible. In a review of animal models for the study of
periodontitis, the NHP model was found to be superior to other animals including
porcine, canine, and rodent models (Table 1). The anatomy of oral structures and teeth
of the NHP is found to be very similar to that of the human as well as the natural
occurrence and formation of dental plaque and calculus. The clinical progression of
periodontitis has also been observed to be similar to the human form of the disease.
7

The only drawbacks of a simian model that were noted were the expensive of acquiring
and maintaining the animals as well as animal husbandry issues i.e. socialization and
mental stimulation, etc.19. A review of non-human primate species found the M. mulatta
to be similar to the human anatomy and disease progression with some differences.
There are histologic similarities in the periodontal tissues as well as the changes in
those tissues from health to disease including widened intercellular spaces, an increase
in PMNs, an increase of inflammatory cells in the connective tissue, destruction of
collagen and formation of deepened periodontal pocketing, and finally bone resorption,
all of which are similarly observed in the human disease progression. The primary
difference noted was a higher proportion of Actinomyces sp. in NHP in both healthy and
diseased sites. Microbiologically, M. mulatta shows an increase in motile rods and
spirochetes with increased inflammation. In established gingivitis lesions the proportion
of anaerobes continues to increase as well as the overall bacterial counts. In
experimentally-induced periodontitis an increase in P. gingivalis and P. intermedia was
observed20.
Table 2. Comparison of animal models available for periodontal research including their anatomical features,
microbiological characteristics, and logistical considerations.

Model

Anatomy

Microbiome

Logistical

Rodent

Only one
incisor and
three molars
per quadrant.
Naturally
occurring
periodontal
disease is
limited.

Microbiota differs from
that of the human. P.
gingivalis and A.
actinomycetemcomitans
do not naturally occur.

Small size makes
procedures
difficult and the
amount of tissue
for analysis is
limited.
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Dog

Oral structures
and teeth, as
well as
periodontal
disease
progression,
differ from that
of the human.

Subgingival plaque
consists of gram (-)
anaerobic cocci and rods
similar to humans
including P. gingivalis
and F. nucleatum.

Animal
regulations issues.
Need for
companionship,
exercise, and
space can be
prohibitive.

Pig

Oral structures
and teeth
similar to
humans.
Naturally
occurring
dental plaque,
calculus, and
periodontal
disease.

Naturally occurring P.
gingivalis, S. mutans,
and A.
actinomycetemcomitans

Relatively
expensive. Animal
care and
maintenance can
be an issue.

Non-Human
Primate

Oral structures
and teeth
similar to
humans.
Naturally
occurring
dental plaque,
calculus, and
periodontal
disease.

Very similar to human.
Naturally occurring P.
gingivalis, A.
actinomycetemcomitans,
Haemophilus spp.,
Actinomyces spp., P.
micra, F. nucleatum, and
E. corrodens, etc.

Expensive.
Extensive animal
care and
enrichment
requirements.

A greater understanding of the subgingival microflora of the M. mulatta species
was gained and correlated to health versus clinically apparent inflammation. Mild
inflammation showed an increase in Haemophilus species (spp.), Actinomyces spp., P.
micra, F. nucleatum, Eikenella corrodens (E. corrodens), and A.
actinomycetemcomitans. The microflora was evaluated 7-days post-scaling and root
9

planing and a considerable increase in aerobes and simultaneous decrease in
anaerobes was observed. The key difference in the NHP was again notably high A.
actinomycetemcomitans in both healthy and diseased sites21. As sequencing
technology improved the microflora of M. mulatta were more thoroughly evaluated and
the findings were correlated to clinical parameters. From a global look at the microbes
present it was found that 56% of the bacteria were identical to or had closely related
human counterparts. Forty-eight species were unique to the macaque but all of these
also had clearly and closely related human counterparts. Health associated microbes
were found to be Streptococcus spp., Lactobacillus spp., and Gemella spp. Periodontal
pathogens associated with clinical inflammation and bone loss were found to be P.
gingivalis, T. forsythia, Filifactor alocis, P. micra, Treponema spp., Fusobacterium spp.,
and A. actinomycetemcomitans.
It was determined that in the M. mulatta a 4mm probing depth (PD) along with
clinical inflammation and bleeding on probing (BOP) is mild periodontitis. A PD of 5mm
or greater with inflammation and BOP is considered moderate to severe periodontitis.
All clinical features found in human periodontitis are present in the M. mulatta including
increased probing depths and bone loss22. Bleeding on Probing (BOP) and its relevance
to disease activity has been studied extensively. It has been reported that the presence
of BOP can have a high false-positive for predicting periodontal breakdown but the
negative predictive value was found to be 98%, meaning that an absence of bleeding is
a reliable predictor of periodontal health23. Both visible inflammation (redness and
edema) of the gingiva and BOP have been correlated histologically to an increase in
inflammatory cell counts as well as collagen breakdown in the periodontal connective
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tissue24,25. Given the value of these clinical findings, a modified Gingival Index (GI)26
and BOP will be evaluated and correlated to the microbiological findings.
This study will aim to expand upon the in vitro research previously completed by
testing the hypothesis that amixicile will selectively inhibit anaerobic periodontal
microbes that code for the PFOR enzyme in in vivo conditions in the Macaca mulatta.
Microflora will be collected, and data recorded for probing depth (PD), clinical
attachment level (CAL), gingival index (GI), plaque index (PI), presence or absence of
calculus (C), and bleeding on probing (BOP) at baseline, immediately post-treatment
and then at 3- and 6- months following a two-week treatment with amixicile. No other
treatment will be rendered.
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Methods
Animals
All animal procedures were performed according to the protocol approved by the
Virginia Commonwealth University (VCU) Institutional Animal Care and Use
Committees (IACUC) (Approval # AD10001255). Two male non-human rhesus
primates, M. mulatta, were used in our study. Animal G’s dentition was healthy and free
of caries or endodontic pathology with tooth #6 having previously treated non-surgical
root canal therapy with an MF amalgam restoration. Animal T’s dentition was healthy
and free of caries or endodontic pathology. The animals were housed at the VCU’s
animal facility in extra-large enclosures. Both subjects were fed a diet of kibble (Monkey
Chow, Purina) and fresh fruits and vegetables as well as foraging for dried seeds, dried
fruits, and nuts daily. They were provided social and environmental enrichment through
daily handling by animal technicians, visual contact with other animals, and other
enrichment items (toys, videos, etc.). Animals enrolled in this study were systemically
healthy.
Clinical Examination and Sample Collection
Clinical periodontal examination was performed by a graduate resident
specializing in periodontics (DL) under the supervision of a faculty periodontist (JGD).
The animals were placed under general anesthesia by way of an injection of ketamine
(10 mg/kg) followed by intubation and administration of 2% isoflurane at 2 L/min and
100% oxygen at 1 L/min. The comprehensive periodontal examination was performed at
baseline, immediately post-treatment, and then at 3- and 6- months post-treatment.
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Baseline exams were performed to determine the clinical and microbiological status of
the animals.
A complete set of clinical photographs was taken at each examination. The
clinical photographs were used to assign a modified Gingival Index (GI)26 score to each
sextant. The scoring was based on the following classification: GI 0 = pale pink to pink,
knife-edge margin, positive architecture; GI 1 = slightly more reddish, slight marginal
edema, clear exudate, no BOP; GI 2 = red to bluish-red, glazy, marginal edema, BOP
apparent in the photograph; GI 3 = markedly red to bluish, edematous,
BOP/spontaneous bleeding apparent in the photograph. Photographs were randomized
and then each sextant was scored with a single value by three independent examiners
(JGD, DL, EB). Scores of each examiner were averaged to come up with the GI of each
sextant for the initial exam, immediately post-amixicile, 3 months post-treatment, and 6
months post-treatment.
Saliva samples were collected using five cotton swabs equally representing all
areas of the mouth by swabbing the entire oral cavity including buccal and sublingual
spaces. The cotton swabs with the sample were placed into microcentrifuge tubes
containing 500 µl of phosphate-buffered saline (PBS, pH 7.2) and RNAlater solution
(Invitrogen, Waltham, Massachusetts, USA).
Gingival crevicular fluid (GCF) and microbiology samples were collected from the
same sites to correlate the findings. Samples of GCF and subgingival plaque were
taken from the following sites at baseline: #1D, 2D, 3D, 14D, 15D, 16D, 20D, 21D, 22D,
27D, 28D, and 29D. Since no mechanical therapy was to be performed as part of the
study, GCF and subgingival plaque samples were taken from #1M, 2M, 3M, 14M, 15M,
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16M, 20M, 21M, 22M, 27M, 28M, 29M for all follow-up exams. For subgingival plaque
collection a Nevi 2 periodontal scaler (SCNEVI29E2, Hu-Friedy, Chicago, Illinois, USA)
was inserted to the base of the attachment and plaque was collected from the
subgingival tooth structure and placed into microcentrifuge tubes containing 500 µl of
phosphate-buffered saline (PBS, pH 7.2) and stored at -80oC. For GCF collection, a
Periostrip paper (Periopaper Gingival Crevicular Fluid Collection Strip, Fisher Scientific
International, Pittsburgh, Pennsylvania, USA) was inserted into the periodontal sulci of
interest and left for 30 seconds or until completely visibly saturated. The samples were
collected into microcentrifuge tubes containing 500 µl of phosphate-buffered saline
(PBS, pH 7.2) and stored at -80oC.

Figure 4. Nonhuman Primate Odontogram showing the position of the teeth in the arch which are very similar to the
human dentition.
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The clinical exam consisted of determination of 1. Probing depth (PD, distance in
millimeters between the gingival margin and the base of the sulcus or pocket) and free
gingival margin (FGM, distance in millimeters from the CEJ to the margin of the
unattached gingiva) measured at four sites per tooth: mesiobuccal, buccal, distobuccal,
and straight palatal or lingual; 2. Clinical attachment level (CAL) was calculated at each
of the aforementioned sites using the formula CAL = PPD – FGM; 3. Presence or
absence bleeding on probing (BOP, Bleeding on Probing); 4. Presence or absence of
plaque (PI, Plaque Index); 5. Presence or absence of calculus.
Baseline exams were performed to determine the periodontal and microbiological
status of the animals. Following the initial exam, the animals were then left for 14 days
without any intervention prior to the administration of amixicile. The animals were then
treated with 40 mg/kg/day of amixicile divided into two doses, encased in marshmallow
for 14 days. No changes were made to the animals’ diet and no oral hygiene measures
were performed during the study period. Periodontal and microbiological exams as
described above were performed immediately post-treatment, 3 months post-treatment,
and 6 months post-treatment (Figure 5).
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Figure 5. Experimental design showing the time frame of the exams and the sequence of events from plaque and
saliva sample collection through analysis.

Microbiological Analysis
For assessment of the microbial content we analyzed both the saliva and
subgingival plaque samples. Each sample for analysis was vigorously vortexed for 5
min to break down any larger plaque complexes. DNA from each sample was extracted
as described below. Plaque samples were processed individually while aliquots of saliva
samples were pooled together prior to analysis.
DNA Isolation. Collected plaque samples were suspended in 500 µl of RNAlater
buffer (Fisher Scientific International, Pittsburgh, Pennsylvania, USA) and stored at 80oC. Genomic DNA (gDNA) was isolated using 200 µl of the mixture with the
PureLinkTM Microbiome DNA purification kit (Fisher Scientific International, Pittsburgh,
Pennsylvania, USA) according to the manufacturer's instructions. Similarly, 200 µl of
pooled saliva was used for DNA isolation.
16

Quantitative PCR (qPCR). The gDNA derived from the above microbiomes was
used to quantify the presence of bacterial species in the various samples using a 7500
Fast Real-time PCR machine (Fisher Scientific International, Pittsburgh, Pennsylvania,
USA). Purified DNA (1 µL) and species-specific primers were added to Fast SYBR
Green Mastermix (Fisher Scientific International, Pittsburgh, Pennsylvania, USA).
Reactions were run using standard cycle conditions: 95°C for 20 sec (1 cycle); 95°C for
3 sec, 60°C for 30 sec (40 cycles). The cycle threshold (Ct) data were collected and
then converted to absolute fold change.
Metagenomic library generation and 16S rDNA Sequencing. Bacterial 16S
ribosomal DNA (rDNA) amplification and library construction were done using the Zymo
Research Quick-16STM NGS Library Prep Kit (Zymo Research, Irvine, California, USA).
Low DNA input protocol was used in our study. Briefly, reactions were set up in 96 well
“Targeted Plate” and the V3-V4 region of rRNA genes were amplified with the V3-V4
primers and the Quick-16STM qPCR Premix. 25 cycles (and more, if required) at the
profile: 95oC for 10 min, 95oC for 30 sec, 55oC for 30 sec, and 72oC for 3 min was used
for amplification. Sufficient amplification was verified using the recommended final
fluorescence (that was higher than the threshold fluorescence). Following cooling at 4oC
the samples were transferred to collection plate and (PCR primers, dNTPs) were
degraded with the enzymatic cleanup solution. Finally, the samples were transferred to
a “barcoded plate” where index primers for multiplexing of the samples were added. The
barcodes were added using 5 PCR cycles consisting of: 95oC for 10 min, 95oC for 30
sec, 55oC for 30 sec, and 72oC for 3 min. Sufficient amplification during barcode
addition was verified through examination of the amplification curve. The library was
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then pooled in equimolar amounts and purified using the MagBead kit components
(Zymo Research, Irvine, California, USA). The final 16S rDNA library was sequenced
with the MiSeq Reagent Kit v3 (600-cycle) with pair end-setting and 2 x 250 bp on the
Illumina MiSeq platform (Illumina, San Diego, California, USA). Sequencing was
performed at the VCU Genomics and Microbiome Core, Richmond, Virginia, USA.
Following sequencing, the samples were deconvoluted, barcodes were trimmed, and
short sequences (<100bp) were removed.
Metagenomic Data Processing. The raw read sequences were analyzed with
CLC Workbench software (version 12; Qiagen, Venlo, Netherlands) equipped with the
Microbial Genomics Module plugin (version 2.0; Qiagen, Venlo, Netherlands). The
paired-end reads were merged into one high-quality representative by settings of CLC
Workbench (mismatch cost = 1, minimum score = 25, gap cost = 4, maximum unaligned
end mismatches = 5). The parameter settings for the quality trimming were as follows:
trim using quality scores, limit = 0.05; trim ambiguous nucleotides, maximum number of
ambiguities = 2. Operational taxonomic unit (OTU) clustering and taxonomic assignment
were carried out with the reference sequences from the Human Oral Microbiome
Database (HOMD, Cambridge, Massachusetts, USA, 16S rRNA gene reference
sequence [16S rRNA refSeq] Version 15.2) at a level of similarity of 97% of OTU.
Bioinformatics Analysis. Data were analyzed using the bioinformatics
workflows available through CLC Genomics Workbench with the CLC Microbial
Genomics Module (Qiagen, Venlo, Netherlands).
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Availability of Data. High throughput sequencing data were deposited to NCBI’s
Sequence Read Archive (SRA) with the accession number SUBXXXX (submission
pending).
Due to the limited sample size and nature of this pilot study, statistical data
analysis will be primarily descriptive in nature with the intent of providing information to
power future studies rather than to determine statistical significance.
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Results
Amixicile reduces clinical periodontal inflammation. The periodontal
examination of both animals revealed mild periodontitis at several sites (Tables 5A,
5B)22. We examined twelve teeth per animal for bleeding on probing (BOP), pocket
depth (PD), and microbiological samples of subgingival plaque and saliva. Three sites
(MB, B, DB) were examined/tooth thus making up thirty-six sites per animal examined.
At the baseline exam for Animal G there were 3 teeth with three sites that had PD of
4mm, which correspond to mild periodontitis for NHP, and seven sites with PD of 3mm
22.

For the second animal, Animal T, there were two teeth, each with one site with PD of

4mm and eleven sites with PD of 3mm. We thus concluded that the clinical
characteristics point to an acceptable level of periodontitis to be used in our study.
A modified Gingival Index (GI) was evaluated in the two specimens examined at
four timepoints during the study period. Agreement on the modified GI between pairs of
independent raters ranged from 0.56 to 0.69 which is considered moderate to
substantial agreement. This amounts to agreement in scores for 71%-79% of images
viewed. Results are given in Table 3.
Table 3. Agreement in Gingival Index when Assessed from Clinical Photos by 3 Independent Raters

Kappa
EEBDJL
JGDEEB
JGDDLL

95% CI Interpretation*

Percent of
Cases Agreed

0.66

0.51-0.81

Substantial

77%

0.56

0.40-0.73

Moderate

71%

0.69

0.54-0.84

Substantial

79%

20

Figure 6. Gingival Index for Animal G and Animal T by Sextant Across Visits

As shown in Figure 6 above, GI was summarized by sextant (Upper Left, Upper
Right, Lower Left, Lower Right). The average GI was calculated by averaging across
the three raters and across all pictures as detailed in the Methods. The trends for GI by
monkey and sextant are given in Figure 6. Data for the GI of Animal G for the Upper
Left sextant was not available. GI was relatively steady on Upper and Lower Left. Upper
Right initially decreased for Animal G and then increased steadily from 3-month and 6month examinations. Animal T increased slightly from Initial to 3-month examinations
and then decreased by the 6-month exam. The Lower Right demonstrated a decrease
from the Initial exam to Post-treatment and then increased at the 3-month exam.
Between the 3-month examination and the 6-month examination, Animal T remained
relatively steady and Animal G had a slight increase in GI score.
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Clinical findings across the study visits are summarized in Table 4. Further
statistical analyses were not performed due to the limited number of animals. Average
probing depth for Animal G increased from initial to both the post-treatment and 3month examination and then decreased by the 6-month follow-up. Animal T saw an
initial decrease at the post-treatment exam followed by an increase at the 3-month visit
and a decrease at 6-months. Both monkeys were at or below their initial average
probing depth by the 6-month examination (Animal G: 2.00 vs 1.99; Animal T: 1.93 vs
1.73; Fig. 6A). In terms of bleeding sites (Fig. 4B), both monkeys saw an initial increase
from the initial examination to the post-treatment followed by a substantial improvement
back to baseline at the 3-month follow-up. By the 6-month follow-up, Animal G had an
additional decrease in bleeding sites, but Animal T saw a slight increase. The number of
plaque sites increased for both monkeys progressively from initial examination through
the 6-month follow-up (Fig. 4C). Both began with 0 plaque sites at the initial examination
and finished with 96 for Animal G and 95 for Animal T.
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Table 4. Summary of Clinical Findings by Visit
Gizmo
Initial
Average Probing
Depth

Post

3 Months

6 Months

2.00

2.09

2.14

1.99

Number of Bleeding
Sites

12

29

17

4

Number of Plaque
Sites

0

51

80

96

UL

UR

UL

UR

UL

UR

UL

UR

2.67

2.17

2.08

1.5

2.17

2.17

2

2.5

LL

LR

LL

LR

LL

LR

LL

LR

--

0.83

0.067

0

1

0.5

0.83

1.17

Gingival Index

Tango
Initial
Average Probing
Depth
Number of Bleeding
Sites
Number of Plaque
Sites

Post

3 Months

6 Months

1.93

1.78

1.91

1.73

4

23

3

9

0

47

84

95

UL

UR

UL

UR

UL

UR

UL

UR

1

1

0.89

0.33

0.83

1

1.4

0.83

LL

LR

LL

LR

LL

LR

LL

LR

0

0

0.2

0.2

0.4

0.5

0.5

0

Gingival Index

In Animal G, twelve of the thirty-six sites (33.3%) exhibited BOP at baseline.
Similarly, in Animal T, there were four sites with BOP out of the thirty-six tested (11.1%).
Immediately following amixicile treatment the number of sites with BOP remained
similar to baseline. Three months post-treatment there were no sites with PD of 4mm in
either animal. There were fourteen sites in animal G and eleven sites in animal T with
PD of 3mm. Significantly, all the sites that previously were 4mm were reduced to 3mm
or less at 3 months post-treatment. Bleeding on probing (BOP) remained similar to
baseline at the 3-month post-treatment exam. At the final exam there were still no sites
measuring 4mm and only eleven sites with PD of 3mm in each of the animals. A
significant reduction in BOP in animal G was noted where we detected four sites, or
11.1%. Animal T experienced a rebound in BOP by the 6-month exam having eight sites
(22.2%) exhibiting BOP. All of the above shows that a two-week treatment with amixicile
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resulted in improvement in BOP in Animal G from 33.3% to 11.1% (Fig. 7) and stability
of PD in Animal G and a reduction in PD in Animal T from 1.93mm at baseline to
1.73mm at the 6-month exam (Table 4, Fig. 8) all while both animals experienced a
dramatic increase of detectable plaque biofilm (Animal G – 51 to 96 sites; Animal T – 47
to 95 sites)(Fig. 9).

Figure 7. Average Probing Depth for Animal G and Animal T Across Visits
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Figure 8. Average Probing Depth for Animal G and Animal T Across Visits

Figure 9. Plaque Sites for Animal G and Animal T Across Visits
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A more focused examination of the effect of amixicile in Animal G shows teeth
that had PD sites of 4mm at baseline included teeth #14, 15, and 16, all of which had
PD of 3mm or less at 6 months post-treatment. At these teeth, BOP decreased from
three sites to one site at three months post-treatment in animal G. That improvement
was maintained through the six-month post-treatment exam. Similarly, in animal T at
teeth #14, 15, and 16, sites with 4mm PD were reduced from two to zero from baseline
through 6-months post-treatment. At these teeth, BOP was decreased to only one site
at 3-months post-treatment, but Animal T experienced a rebound between 3 and 6
months ending with three sites with BOP.
Table 5. Clinical characteristics of Animal G at baseline (-B), Post-amixicile (-P), 3-months post-treatment (-3), and 6months post-treatment (-6). Clinical characteristics assessed: PD – pocket depth (shown in mm), BOP – bleeding on
probing (B – bleeding, N – no bleeding)
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Table 6. Clinical characteristics of Animal T at baseline (-B), Post-amixicile (-P), 3-months post-treatment (-3), and 6months post-treatment (-6). Clinical characteristics assessed: PD – pocket depth (shown in mm), BOP – bleeding on
probing (B – bleeding, N – no bleeding)

Amixicile reduces the abundance of anaerobic bacteria within the salivary
microbiome. Saliva from all sites has been collected and pooled prior to analysis.
Aliquots of saliva collected during baseline and follow up periodontal exams have been
used to isolate total DNA. The DNA was used for 16S rDNA sequencing and data was
analyzed at the genus and species level (Fig. 10-13). Analysis of the data derived from
Animal G at the genus level revealed that at baseline the most dominant were bacteria
belonging to the Streptococcus genus followed by Haemophilus, Porphyromonas,
Gemella, and Fusobacterium genera (Fig. 10). In the second animal, Animal T, bacteria
belonging to the Neisseria genus were the most abundant while bacteria belonging to
the genera of Porphyromonas, Streptococcus, and Gemella were also abundant (Fig.
12). Having large proportions of anaerobic bacteria, specifically bacteria belonging to
Porphyromonas and Fusobacterium, justified the use of this model for testing of
amixicile’s efficacy. Following treatment with amixicile, reduction in anaerobic bacteria
with a concomitant increase in aerotolerant ones was observed. Specifically, a reduction
in bacteria belonging to the genera Porphyromonas, Fusobacterium, and Alloprevotella,
all anaerobes, was seen in Animal G. At the same time, an increase in Haemophilus,
Gemella, and Escherichia, all aerobes, was detected (Fig. 10). At the species level,
Animal G showed a dramatic reduction of F. nucleatum immediately post-treatment with
some rebound through 6-months but never reaching pre-treatment levels (Fig. 11).
Streptococcus remained at similar levels to the pre-treatment phase. In the second
animal, Animal T, we also observed a reduction in bacteria belonging to Porphyromonas
(Fig. 12). However, a reduction in Neisseria, an obligate aerobe, was also observed. An
increase in levels of aerotolerant bacteria belonging to the Streptococcus, Haemophilus,
and Gemella genera was observed (Fig. 12). These results demonstrate that amixicile
was effective in reducing the levels of anaerobic bacteria present in the salivary
microbiome of an NHP model while leaving the aerobic species generally unaffected.

27

Figure 10. Amixicile reduces the abundance of anaerobic bacteria within the salivary microbiome. Animal G – Genus
level analysis.

Figure 11. Amixicile reduces the abundance of anaerobic bacteria within the salivary microbiome. Animal G –
Species-level analysis.
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Figure 12. Amixicile reduces the abundance of anaerobic bacteria within the salivary microbiome. Animal T – Genus
level analysis.

Figure 13. Amixicile reduces the abundance of anaerobic bacteria within the salivary microbiome. Animal T –
Species-level analysis.
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Amixicile reduces the abundance of anaerobic bacteria in gingival pockets.
Four sites of subgingival plaque biofilm from Animal G (#3,14,16,22) and four sites from
Animal T (#3,14,15,16) were successfully surveyed for the composition of the oral
microbiome at baseline and following amixicile treatment (Fig. 14-17). Survey of the G3
(Animal G, tooth #3) site at the genus level in Animal G indicated that at baseline
Porphyromonas and Fusobacterium were highly dominant. Other abundant bacteria
included Leptotrichia, Prevotella, and Streptococcus. Following amixicile treatment a
significant reduction in both Porphyromonas and Fusobacterium levels was observed.
This corresponded to an increase in levels of Leptotrichia and Prevotella (Fig. 14).
Analysis of the G14 site has shown that at baseline Escherichia, Prevotella and
Streptococcus were highly abundant genera (Fig. 15). Following amixicile treatment
levels of Escherichia and Prevotella were reduced while those of Leptotrichia and
Fusobacterium were increased. Baseline abundance of the G16 site has shown high
levels of Escherichia, Veillonella, Streptococcus, Leptotrichia, Prevotella, and
Fusobacterium (Fig. 16). Following treatment, the abundance of Veillonella,
Streptococcus, Leptotrichia, Prevotella, and Fusobacterium were reduced while that of
Escherichia, Actinomyces, and Aggregatibacter was elevated. The fourth site of Animal
G, G22, has shown a high abundance of Escherichia, Porphyromonas, Prevotella,
Fusobacterium, and Alloprevotella. Following antibiotic treatment, the levels of
Porphyromonas, Fusobacterium, and Alloprevotella were reduced with an increase in
Leptotrichia, Selenomonas, Prevotella, and Actinomyces. Interestingly, levels of
Streptococcus were also reduced (Fig. 17). Overall, in Animal G we observed a
reduction in levels of anaerobic bacteria and an increase in abundance of aerotolerant
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ones. There was significant variation in the microbial composition of the baseline
microbiome as well as post-treatment.

Figure 14. Amixicile reduces the abundance of anaerobic bacteria within the subgingival microbiome, site-specific
analysis – Site G3.

Figure 15. Amixicile reduces the abundance of anaerobic bacteria within the subgingival microbiome, site-specific
analysis – Site G14.
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Figure 16. Amixicile reduces the abundance of anaerobic bacteria within the subgingival microbiome, site-specific
analysis – Site G16.

Figure 17. Amixicile reduces the abundance of anaerobic bacteria within the subgingival microbiome, site-specific
analysis – Site G22.
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Analysis of the subgingival microbiomes of Animal T, both at baseline and posttreatment has shown a similar trend in that levels of anaerobic bacteria were reduced in
favor of the aerobic ones (Fig. 18-21). Specifically, the abundant genera of T3 (Animal
T, tooth #3) were Escherichia, Streptococcus, Porphyromonas, and Prevotella.
Following amixicile treatment the abundance of Prevotella was significantly reduced.
Increased levels of Escherichia, Streptococcus, Aggregatibacter, and Peptidiphaga
were observed (Fig. 18). At the second site of the Animal T, T14, Streptococcus,
Porphyromonas, and Fusobacterium were the dominant bacterial genera. After amixicile
treatment, the levels of Porphyromonas, Fusobacterium, and Streptococcus were
significantly reduced. That corresponded to an increase in levels of Escherichia,
Aggregatibacter, and Peptidiphaga (Fig. 19). The T15 site at baseline was abundant in
Escherichia, Streptococcus, Porphyromonas, and Haemophilus. Following amixicile
treatment the levels of Porphyromonas, Streptococcus, Haemophilus, and
Fusobacterium were significantly reduced with an increase in the levels of Leptotrichia
and Bacteroides (Fig. 20). The final site analyzed for microbiome composition, T16, had
high levels of Escherichia at baseline that were reduced with a concomitant increase in
levels of Streptococcus (Fig. 21). Thus, similar to Animal G, we observed high variability
between the microbial composition of samples derived from different sites. However, the
common theme from all the treated sites was a reduction in the abundance of anaerobic
bacteria and an increase in levels of aerotolerant ones. In conclusion, amixicile
effectively reduced levels of subgingival anaerobic bacteria in the treated samples while
sparing the aerotolerant ones.
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Figure 18. Amixicile reduces the abundance of anaerobic bacteria within the subgingival microbiome, site-specific
analysis – Site T3.

Figure 19. Amixicile reduces the abundance of anaerobic bacteria within the subgingival microbiome, site-specific
analysis – Site T14.
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Figure 20. Amixicile reduces the abundance of anaerobic bacteria within the subgingival microbiome, site-specific
analysis – Site T15.

Figure 21. Amixicile reduces the abundance of anaerobic bacteria within the subgingival microbiome, site-specific
analysis – Site T16.
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The effect of amixicile on the oral microbiome is reversed after several
months post-treatment. We followed the animals’ microbiome changes up to six
months post-treatment. Between 1- and 6- months post-treatment the salivary
microbiome of Animal G had an increase in the abundance in Porphyromonas,
Fusobacterium, and Leptotrichia while reduction in Haemophilus, Streptococcus, and
Gemella was observed. The composition resembled the baseline microbiome, however,
higher levels of Leptotrichia were seen. In Animal T, the salivary microbiome had higher
levels of Haemophilus and Fusobacterium at longer post-treatment intervals. In the
subgingival microbiome, an increase in the proportion of anaerobic bacteria was also
observed after longer timeframes.
Correlation between microbiome and clinical characteristics. Significant
clinical improvement as determined by PD, BOP, and GI was observed at three months
post-treatment and continued into the sixth month. The clinical improvements were
delayed with respect to the onset of the reduction of anaerobic bacteria in the
microbiome. At six months, despite some reversal of the abundance of anaerobic
bacteria to near baseline levels the clinical improvement persisted.
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Discussion
The work presented here shows that the use of a 14-day treatment of amixicile at
40mg/kg/day is effective in reducing the symptoms of periodontal disease as manifested
by probing depths (PD) and bleeding on probing (BOP). While the average PD
remained relatively steady, all sites measuring 4mm (mild periodontitis in an NHP
model) were reduced to 3mm or less by 3-months post-treatment, and this reduction
was maintained through the endpoint of the study at 6 months. Similarly, reduction in
gingival index (GI) was more notable at specific sites (Photo 1, A-C), which were not
adequately captured in the average scores. Interestingly, bleeding on probing (BOP)
increased immediately following the 14-day course of amixicile but then decreased
dramatically at 3- and 6-months follow-up. This does not readily correlate to the GI
scores given each animal at the designated timeframes. A striking observation is that
while all of these clinical indices were either decreasing or remaining stable the sites
with plaque were steadily and dramatically increasing (Fig. 6C). A possible explanation
may be that although there is an increase in the number of microbes, the balance could
be shifted to a plaque rich in commensal, aerobic bacteria due to amixicile’s selective
targeting of the anaerobic periodontal pathogens. Without microbes belonging to the
more virulent periodontal complexes described above there may be no inflammatory
response by the host and thus, no periodontal inflammation.
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It is noteworthy that we also see the conversion of the composition of the salivary
and sulcular microbiomes from one prevalent in anaerobic bacteria to one with reduced
levels of anaerobes and increased proportions of aerotolerant microorganisms (Fig. 1021). In the saliva samples a reduction in Porphyromonas, Fusobacterium, and
Alloprevotella, all anaerobes, was seen with a concomitant increase in Streptococcus,
Haemophilus, Gemella, and Escherichia, all aerobes, was observed. Subgingival plaque
samples showed similar alterations in microbial composition. Reduction of
Porphyromonas, Fusobacterium, Prevotella, Veillonella, and Alloprevotella, all
anaerobes, was observed with concomitant increase of known aerobes. These changes
generally take place immediately post-treatment but return to baseline levels by 6months.
There was a great degree of variability in microbial composition between
individual sites which would be expected but makes comparison difficult. Microbial
composition likely varies based on the depth of sulcus as well as environmental factors
such as chewing function and self-cleansability. The lack of diversity of microflora in
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Animal T, site #16 at baseline is noteworthy (Fig. 21). This site had very little biofilm and
was periodontally healthy at the initial exam. With such a small amount of biomass the
DNA had to amplified many times to yield any data. This means that only microbes
present in high abundance would be represented in the data and that it is uncertain
which others may be present at low abundance. As the biofilm accumulated a more
diverse flora is noted at the 6-month exam.
When all the above data is taken together it seems that the microbiological
effects of amixicile precede the clinical benefits. Although the microbiome tends to
rebound between 3- and 6-months the clinical improvements persisted through the 6month exam.
Limitations to our study include a small sample size of only two non-human
primates as the expense of acquiring and maintaining these animals is very great.
Given that only two subjects were available for study both animals received the
treatment so there was no control in our study. The animals also only exhibited mild
periodontitis at worst in a small number of sites. Another limitation is that we were
unable to measure the concentration of amixicile or any inflammatory markers in the
GCF or serum so while the microbiological data would support its action it can’t be
determined how well it was able to localize to the gingival sulcus. In our study V3-V4
primers were used which allow for broader phylogenetic coverage that V1-V2 primers.
This is both an advantage and a disadvantage as these primers target 16S rDNA, but
different strains of microbes cannot be distinguished using this method.
The microbiological findings support the hypothesis that amixicile reduces the
proportion of anaerobic microorganisms in the oral cavity, many of which are
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periodontal pathogens. These findings coupled with a reduction of clinical periodontal
inflammation suggest that further study of amixicile for the treatment of periodontitis is
warranted. Future studies should have a larger sample size and should include a
negative control. Ideally, subjects would have more severe forms of periodontitis, and
other antibiotics, possibly broad-spectrum, could be used for comparison or potentially
in conjunction with amixicile.
The clinical implications of this study show great promise in amixicile as a novel
antimicrobial for the treatment of periodontal disease. If amixicile continues to be found
successful at selectively targeting periodontal pathogens with little to no side effects it
may not only replace current antimicrobial options, such as the combination of
Amoxicillin and Metronidazole, but it may make its use more routine for the treatment of
periodontitis. In our study a 14-day course caused a significant reduction in pathogenic
bacteria with a rebound of the microbes occurring between 3-6 months. With no side
effects it may be possible to prescribe a 14-day course of amixicile once every 3-6
months as needed for patients with persistent periodontal inflammation.
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Conclusion
In conclusion, amixicile seems to be a strong candidate as a viable antimicrobial
option for the treatment of periodontal disease. It selectively inhibits known anaerobic
periodontal pathogens including Porphyromonas spp., Fusobacterium spp., and
Prevotella spp. causing a reduction in clinical periodontal symptoms for a period of up to
six months. Further research at a larger scale is needed to bring the drug closer to the
possibility of a clinical trial in humans.
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